EIT Health Investor Network Lounge – Your chance to pitch in front of EIT Health Investor Network

Two spots are available for the upcoming EIT Health Investor Network Lounge in November 2020. Apply now and get the opportunity to meet the EIT Health Investor Network.

Securing funding for a growing startup is an overwhelmingly difficult and complex process, but it is essential to get investors’ interest. The EIT Health Investor Network can help you to navigate that process.

EIT Health Investor Network is the first pan-European, EU-driven network solely focused on financing healthcare innovation. Part of EIT Health Accelerator, the Investor Network aims to connect European health-oriented investors with promising, pre-screened start-ups, so that ideas for improving healthcare can get into the market.

On 4 November 2020, EIT Health Germany is organizing an Investor Network Lounge, together with Janssen-Cilag, the EIT Health Investor Network, Business Angels Connect and BIO.NRW. The goal of the event is to match a top selection of EIT Health promoted startups from all over Europe with selected Venture Capital Companies & Business Angels to facilitate upcoming investment rounds.

EIT Health Germany is inviting start-ups interested in pitching in front of EIT Health Investor Network to send their expressions of interest for the two available spots at the event.

If your start-up:

  • Is working in the BioTech sphere
  • Is a European registered company raising a Seed or Series A round of funding
  • Is interested in meeting the EIT Health Investor Network?

Then, this is your chance. Apply today and get the opportunity to win one of two spots available.

Expressions of interest should be sent until 30 September 2020 to Mathis Palm ( Applications will be processed on a first-come, first-served basis.

In recent months a number of financing rounds could be brokered by the Investor Network. TeiaCare collected €1.1m, Wefight raised €1.8m and InHeart received €3.7m. As recent as July 2020, two members of Investor Network, BioMedPartners and Seventure helped to finalize a Series A financing round of €10.7m for Tubulis. The company’s development of a new generation of antibody-drug conjugates is now accelerating thanks to the EIT Health ecosystem collaboration.